Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03570476 · ClinicalTrials.gov registry record · Phase 2
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03570476 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 2 participants.
The verdict
NCT03570476, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase II trial studies how well olaparib works in treating participants with prostate cancer that has not spread to other parts of the body (localized). Olaparib may stop the growth of tumor cells by interfering with the activity of a substance called PARP, which is inside cells. Giving olaparib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
- DRUG Olaparib
- PROCEDURE Radical Prostatectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-09-11 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03570476
The ClinicalTrials.gov registry entry for NCT03570476 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olaparib is the first listed.
NCT03570476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03570476 about?
NCT03570476 is a clinical study titled "Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer". This phase II trial studies how well olaparib works in treating participants with prostate cancer that has not spread to other parts of the body (localized). Olaparib may stop the growth of tumor cells by interfering with the activity of a substance called PARP, which is inside cells. Giving olapari...
What is the current status of trial NCT03570476?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2018-09-11. Estimated completion is 2019-07-03.
What interventions are being tested in trial NCT03570476?
The interventions under investigation include: Olaparib (DRUG), Radical Prostatectomy (PROCEDURE).
Who is sponsoring clinical trial NCT03570476?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.